the mechanism question that gets asked weekly, answered properly
the mechanism question that gets asked weekly, answered properly. Change my mind, genuinely — I have no stake in being right about this.
Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Asked for a citation rather than removing. On this board a claim without one is an invitation, not an offence.
receptor agonism is not the same as receptor activation in every tissue
glucagon agonism sounds paradoxical until you read the energy expenditure work
Does the effect persist with continued dosing or does tolerance develop?
Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
read the discussion section, that is where the honesty lives
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
dose response is not linear and nobody should assume it is
gastric emptying slows, it does not stop
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
The GIP question, which is the most interesting unsettled thing in this field.
Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.
It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.
- 1Glucose-dependent insulin secretion is why hypoglycaemia risk is low as…12 comments in this branch · started by u/nora_lundgren